

1.	<p><b>Treatment &amp; Condition</b></p> <p>Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia</p>
2.	<p><b>Associated appraisal body &amp; Summary of ruling</b></p> <p>NICE Technology appraisal guidance [TA694] Published: 28 April 2021  <a href="https://www.nice.org.uk/guidance/TA694">https://www.nice.org.uk/guidance/TA694</a></p> <ul style="list-style-type: none"> <li>• Bempedoic acid with ezetimibe is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if: <ul style="list-style-type: none"> <li>○ statins are contraindicated or not tolerated</li> <li>○ ezetimibe alone does not control low-density lipoprotein cholesterol well enough and</li> <li>○ the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement.</li> </ul> </li> </ul> <p>Bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination.</p> <ul style="list-style-type: none"> <li>• This recommendation is not intended to affect treatment with bempedoic acid with ezetimibe that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.</li> </ul>
3.	<p><b>Number of people in Northern Ireland expected to take up service/therapy</b></p>
4.	<p><b>Patient Access Scheme Availability (Yes/No)</b></p> <p>There is a commercial access agreement for bempedoic acid and bempedoic acid with ezetimibe.</p>
5.	<p><b>Infrastructure Requirements</b></p> <p>Any additional infrastructure costs associated will be dealt with as part of the routine commissioning process.</p>
6.	<p><b>Expected implementation period</b></p> <p>There is no impediment to immediate implementation for new patients.</p>

<b>7.</b>	<b>Commissioning arrangements</b>  Bempedoic acid with ezetimibe for this indication is commissioned by HSCB. Providers are HSC hospital trusts, and primary care.
<b>8.</b>	<b>Monitoring arrangements</b>  Through usual monitoring of primary care drug budgets.
<b>9.</b>	<b>DoH (NI) Legislative/Policy Caveats</b>  This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.  The Rural Needs Act NI 2016 has been considered and this guidance, which is purely of a technical nature, is not regarded as falling within the scope of the act.